RecruitingNCT03646058
Study of low-dose buprenorphine for suicidal thoughts in depression
About this title
Read the official source — NCT03646058Medication studyAges 18–65France
Understand this study
Who could participate?
Listed age limits: 18 years to 65 years.
- Listed locations
- Bordeaux and 8 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: October 10, 2021
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 180
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- France
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT03646058
- Official title
Show the full official title
Add-on Buprenorphine at Analgesic Doses for the Treatment of Severe Suicidal Ideas During a Major Depressive Episode
Recruitment & locations
RecruitingBordeaux · Le Kremlin-Bicêtre · Lyon
6 more locations
- Nantes
- Nîmes
- Paris
- Poitiers
- Toulouse
- Tours
A listed location does not confirm current availability.
Questions about this study
Who is behind this study?
The study sponsor is Centre Hospitalier Universitaire de Nīmes.
Does this study involve medication?
Yes. The study involves medication, including Buprenorphine and Placebo.
Who can participate?
Listed age limits: 18 years to 65 years.
Is this study still recruiting?
The registry lists this study as recruiting.
